

Global e·dentity™ plans to release the first patented automated electronic sensor technology to detect Covid-19 by smell

Wilmington, DE –Dec 02, 2021 — An American tech start-up has patented the first biotechnology solution enabling users to instantly detect pre-symptomatic or asymptomatic Covid-19 infections through unique odors emitted by the human body.

Global e·dentity's™ newest patent US 10,880,303 is the first U.S. patent issued to detect the Covid family of viruses by its biometric identity from markers using chemosensory scanning of the (VOCs) a.k.a Volatile Organic Compounds or smell associated with the unique chemical odor signature associated with the metabolism of Covid-19 infection, thus quickly identifying individuals who are asymptomatic or pre-symptomatic.

The technology pairs organic semiconducting (OSC) sensors and other sensor equipment that, when combined with artificial intelligence, acts like a dog's nose or chemical sniffer on steroids that can detect drugs or explosives but, in this case, Covid-19.

Global e·dentity's™ new patented method provides the world with a new capability to easily identify asymptomatic or pre-symptomatic Covid-19 carriers, whether vaccinated or not, eliminating the need for vaccine passports while creating a huge potential breakthrough opportunity for global ports of entry around the world. Global e·dentity™ Founder Robert Adams spoke about the tremendous potential of his technology for proactive health screening more than two years ago, at TEDx, Norwich, England, in July 2019 (watch here:

https://www.ted.com/talks/dr_robert_adams_in_our_hands_the_future_of_proactive_health_is_only_a_heartbeat_away)

While RT-PCR testing is being conducted at some global ports of entry, these efforts can be slow and costly. As detailed in a recent London School of Hygiene and Tropical Medicine, University of

London research paper (<https://www.lshrm.ac.uk/media/49791>), real-time RT-PCR & NAT testing may be unsuitable for mass screening, but the use of trained bio-detection dogs and/or electronic sensor technology such as that pioneered by Global e·identity™ is ideal for real-time mass screening of travelers to identify those who may be Covid-positive.

Global e·identity™ has worked throughout 2021 to position the company to bring the world's first mass-use, fully automated biometrics Covid detection system to market, capable of clearing a person as Covid-free within seconds, no matter the genetic variant, using just smell, starting with airports and immigration points, and later extending to restaurants, office buildings, and public events and venues.

Alongside licensed strategic partners and manufacturers, Global e·identity™ anticipates deploying biometric Covid detection scanners at airports and border crossing locations in early 2022.

Global e·identity™ Inc. is a leading provider of multi-factor bio-metric, digital identity solutions, and now health biometrics, the company is a privately registered corporation in Delaware U.S.A. with plans for an IPO in 23-24. www.globaledentity.com. Global e·identity™ is a registered trademark of Global e·identity™ For more information, press only: Sophia Miller: somiller@globaledentity.com